Since Ozempic entered India last year, clinics have seen a surge in weight‑loss seekers. Dr Reema Arora of The Face Clinic in New Delhi reports a 30 % rise in patients, and she expects demand to accelerate now that the Indian patent on semaglutide has expired. Novo Nordisk faces a flood of generic competitors eager to capture price‑sensitive consumers. Urban middle‑class earners are driving the trend.

Ten domestic firms have already launched their own semaglutide brands, sparking what an industry insider called a “bloodbath”. Analysts at Jefferies value India’s weight‑loss market at $500 million‑$1 billion, while Nomura estimates monthly prices of Rs3,500‑Rs8,000 ($37‑$85) for disposable pens versus Rs11,000‑Rs16,000 for branded versions. The price war threatens the margins of Western pioneers. Insurers are also watching the price dynamics closely.

Biocon, led by billionaire Kiran Mazumdar‑Shaw, is scaling production in Bengaluru and signing deals to export semaglutide to 23 countries, eyeing the same trajectory as statins. Yet domestic competition remains fierce; Novo Nordisk warns U.S. sales could dip 13 % as Indian pricing pressure spreads. Ultimately, Indian consumers will gain cheaper access, but quality control will test brand trust. Regulators will need to enforce stringent standards.